The clinical features, therapeutic effects and prognosis of mantle cell lymphoma.
- Author:
Hai-xi ZHANG
1
;
Juan XU
;
Ting LIU
;
Cai-gang XU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Disease-Free Survival; Female; Humans; Lymphoma, Mantle-Cell; diagnosis; drug therapy; mortality; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis
- From: Chinese Journal of Hematology 2011;32(4):231-235
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze clinical features, therapeutic effects and prognostic factors of patients with mantle cell lymphoma (MCL).
METHODSClinical data of 37 MCL patients hospitalized in our hospital from January 2000 to March 2010 were retrospectively analyzed.
RESULTSThe median age was 62, with a male predominance. 97.30% of the patients were in Ann Arbor stage III ∼ IV, 54.05% with B symptoms, 64.86% with bone marrow involvement, 29.73% with splenomegaly, 24.32% with lymphocytosis and 51.35% with elevated LDH. Ki-67 was detected in 22 cases, and patients with Ki-67 ≤ 40% accounted for 68.18%. Of 37 cases, the overall response rate (ORR) of rituximab combined with chemotherapy was 92.31%, being higher than those of CHOP (46.15%) and CHOP + IFN (42.86%) regimens. There were statistical differences in the 3-year progression-free survival (PFS) and overall survival (OS) between rituximab + chemotherapy and CHOP or CHOP + interferon regimens (P < 0.05, respectively). Splenomegaly, elevated WBC, lymphocytosis and Ki-67 > 40% were identified as adverse prognostic factors.
CONCLUSIONMost patients with MCL were older adults, with a male predominance and usually had bone marrow involvement and poor prognosis. Rituximab combined with chemotherapy could improve ORR and OS of MCL.
